Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) Sees Significant Increase in Short Interest

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totaling 79,267 shares, a growth of 284.8% from the April 30th total of 20,598 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average trading volume of 61,665 shares, the days-to-cover ratio is currently 1.3 days.

Otsuka Trading Up 3.8%

Shares of Otsuka stock traded up $1.33 during trading hours on Friday, reaching $36.46. 7,612 shares of the company’s stock were exchanged, compared to its average volume of 37,048. Otsuka has a 52-week low of $21.68 and a 52-week high of $37.52. The company has a fifty day moving average of $34.87 and a 200-day moving average of $31.79. The company has a current ratio of 2.17, a quick ratio of 1.67 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $39.16 billion and a price-to-earnings ratio of 15.38.

Otsuka (OTCMKTS:OTSKY) last released its earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.16. Otsuka had a net margin of 15.01% and a return on equity of 12.33%. The firm had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. Sell-side analysts forecast that Otsuka will post 1.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Zacks Research raised Otsuka from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 31st. The Goldman Sachs Group cut Otsuka from a “strong-buy” rating to a “strong sell” rating in a research note on Friday, February 27th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold”.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.